{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:40:05Z","timestamp":1751485205215,"version":"3.41.0"},"reference-count":17,"publisher":"International College of Surgeons","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"abstract":"Abstract<\/jats:title>\n A 39-year-old man received a diagnosis of unresectable multiple liver metastases from multiple colorectal cancers with familial adenomatous polyposis. After construction of an ileostomy, modified FOLFOX6 (mFOLFOX6) with panitumumab was administrated because rectal cancer and sigmoid colon cancer are KRAS wild type. The 13 courses of chemotherapy resulted in a marked reduction in the size of liver metastases and sigmoid colon cancer. Consequently, curative resection with total colectomy, ileal pouch anal anastomosis, and liver metastasis resection with radiofrequency ablation was performed. Progression of KRAS wild-type rectal cancer after chemotherapy suggested that each clone from rectal and sigmoid colon cancer might have a different sensitivity to epidermal growth factor receptor antibody. Immunohistochemical analysis revealed loss of PTEN expression in rectal cancer compared with liver metastases from sigmoid colon cancer, showing that the difference of mFOLFOX6 with panitumumab might be related to activation of the PI3K-AKT pathway.<\/jats:p>","DOI":"10.9738\/intsurg-d-13-00125.1","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T00:06:49Z","timestamp":1417478809000},"page":"795-801","source":"Crossref","is-referenced-by-count":2,"title":["Conversion Therapy Using mFOLFOX6 With Panitumumab for Unresectable Liver Metastases From Multiple Colorectal Cancers With Familial Adenomatous Polyposis"],"prefix":"10.9738","volume":"99","author":[{"given":"Yuji","family":"Toiyama","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Kitajima","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Okigami","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinaga","family":"Okugawa","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyunichiro","family":"Hiro","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Mohri","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kusunoki","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4721","reference":[{"issue":"8","key":"i0020-8868-99-6-795-b01","series-title":"Br J Surg","first-page":"1136","article-title":"Late results justify resection for multiple hepatic metastases from colorectal cancer","volume":"84","author":"Rees\n M,","year":"1997","unstructured":"Rees\n M, \n \n Plant\n G, \n \n Bygrave\n S. \n \n Late results justify resection for multiple hepatic metastases from colorectal cancer. Br J Surg1997;84(8):1136\u20131140"},{"issue":"8","key":"i0020-8868-99-6-795-b02","series-title":"Dis Colon Rectum","first-page":"1089","article-title":"Functional results after the Orr-Loygue transabdominal rectopexy for complete rectal prolapse","volume":"46","author":"Douard\n R,","year":"2003","unstructured":"Douard\n R, \n \n Frileux\n P, \n \n Brunel\n M, \n \n Attal\n E, \n \n Tiret\n E, \n \n Parc\n R. \n \n Functional results after the Orr-Loygue transabdominal rectopexy for complete rectal prolapse. Dis Colon Rectum2003;46(8):1089\u20131096"},{"issue":"8","key":"i0020-8868-99-6-795-b03","series-title":"J Surg Oncol","first-page":"922","article-title":"Evolution of neoadjuvant therapy for extended hepatic metastases\u2013have we reached our (non-resectable) limit?","volume":"102","author":"Adam\n R,","year":"2010","unstructured":"Adam\n R, \n \n Hoti\n E, \n \n Bredt\n LC. \n \n Evolution of neoadjuvant therapy for extended hepatic metastases\u2013have we reached our (non-resectable) limit?\n J Surg Oncol\n 2010;102(8):922\u2013931"},{"issue":"18","key":"i0020-8868-99-6-795-b04","series-title":"J Clin Oncol","first-page":"2702","article-title":"Downstaging or downsizing: time for a new staging system in advanced colorectal cancer?","volume":"24","author":"Poston\n G,","year":"2006","unstructured":"Poston\n G, \n \n Adam\n R, \n \n Vauthey\n JN. \n \n Downstaging or downsizing: time for a new staging system in advanced colorectal cancer?\n J Clin Oncol\n 2006;24(18):2702\u20132706"},{"issue":"2","key":"i0020-8868-99-6-795-b05","series-title":"Cancer Chemother Pharmacol","first-page":"209","article-title":"Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials","volume":"66","author":"Nasti\n G,","year":"2010","unstructured":"Nasti\n G, \n \n Ottaiano\n A, \n \n Berretta\n M, \n \n Delrio\n P, \n \n Izzo\n F, \n \n Cassata\n A\n \n et al\n . Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemother Pharmacol2010;66(2):209\u2013218"},{"issue":"31","key":"i0020-8868-99-6-795-b06","series-title":"J Clin Oncol","first-page":"4697","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard\n JY,","year":"2010","unstructured":"Douillard\n JY, \n \n Siena\n S, \n \n Cassidy\n J, \n \n Tabernero\n J, \n \n Burkes\n R, \n \n Barugel\n M\n \n et al\n . Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol2010;28(31):4697\u20134705"},{"issue":"10","key":"i0020-8868-99-6-795-b07","series-title":"J Clin Oncol","first-page":"1626","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado\n RG,","year":"2008","unstructured":"Amado\n RG, \n \n Wolf\n M, \n \n Peeters\n M, \n \n Van Cutsem\n E, \n \n Siena\n S, \n \n Freeman\n DJ\n \n et al\n . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol2008;26(10):1626\u20131634"},{"issue":"14","key":"i0020-8868-99-6-795-b08","series-title":"N Engl J Med","first-page":"1408","article-title":"Chang Chien CR, Makhson A et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem\n E,","year":"2009","unstructured":"Van Cutsem\n E, \n \n Kohne\n CH, \n \n Hitre\n E, \n \n Zaluski\n J, \n \n Chang Chien CR, Makhson A et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med2009;360(14):1408\u20131417"},{"issue":"5","key":"i0020-8868-99-6-795-b09","series-title":"J Clin Oncol","first-page":"663","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer\n C,","year":"2009","unstructured":"Bokemeyer\n C, \n \n Bondarenko\n I, \n \n Makhson\n A, \n \n Hartmann\n JT, \n \n Aparicio\n J, \n \n de Braud\n F\n \n et al\n . Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol2009;27(5):663\u2013671"},{"issue":"10","key":"i0020-8868-99-6-795-b10","series-title":"Eur J Cancer","first-page":"1466","article-title":"Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials","volume":"48","author":"Bokemeyer\n C,","year":"2012","unstructured":"Bokemeyer\n C, \n \n Van Cutsem\n E, \n \n Rougier\n P, \n \n Ciardiello\n F, \n \n Heeger\n S, \n \n Schlichting\n M\n \n et al\n . Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer2012;48(10):1466\u20131475"},{"issue":"9783","key":"i0020-8868-99-6-795-b11","series-title":"Lancet","first-page":"2103","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan\n TS,","year":"2011","unstructured":"Maughan\n TS, \n \n Adams\n RA, \n \n Smith\n CG, \n \n Meade\n AM, \n \n Seymour\n MT, \n \n Wilson\n RH\n \n et al\n . Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet2011;377(9783):2103\u20132114"},{"key":"i0020-8868-99-6-795-b12","series-title":"J Clin Oncol","article-title":"Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): resections and curative surgery in a phase II single arm, multicenter study","volume":"28","author":"Hofheinz\n R,","year":"2010","unstructured":"Hofheinz\n R, \n \n Mineur\n L, \n \n Greil\n R, \n \n Kohne\n C, \n \n Letocha\n H, \n \n Thaler\n J\n \n et al\n . Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): resections and curative surgery in a phase II single arm, multicenter study ( 20060314). J Clin Oncol (Meeting Abstracts)2010;28(15_suppl 3545)"},{"issue":"8","key":"i0020-8868-99-6-795-b13","series-title":"Cancer Res","first-page":"3992","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Lievre\n A,","year":"2006","unstructured":"Lievre\n A, \n \n Bachet\n JB, \n \n Le Corre\n D, \n \n Boige\n V, \n \n Landi\n B, \n \n Emile\n JF\n \n et al\n . KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res2006;66(8):3992\u20133995"},{"issue":"17","key":"i0020-8868-99-6-795-b14","series-title":"N Engl J Med","first-page":"1757","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis\n CS,","year":"2008","unstructured":"Karapetis\n CS, \n \n Khambata-Ford\n S, \n \n Jonker\n DJ, \n \n O'Callaghan\n CJ, \n \n Tu\n D, \n \n Tebbutt\n NC\n \n et al\n . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med2008;359(17):1757\u20131765"},{"issue":"35","key":"i0020-8868-99-6-795-b15","series-title":"J Clin Oncol","first-page":"5705","article-title":"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer","volume":"26","author":"Di Nicolantonio\n F,","year":"2008","unstructured":"Di Nicolantonio\n F, \n \n Martini\n M, \n \n Molinari\n F, \n \n Sartore-Bianchi\n A, \n \n Arena\n S, \n \n Saletti\n P\n \n et al\n . Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol2008;26(35):5705\u20135712"},{"issue":"5","key":"i0020-8868-99-6-795-b16","series-title":"Cancer Res","first-page":"1851","article-title":"PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies","volume":"69","author":"Sartore-Bianchi\n A,","year":"2009","unstructured":"Sartore-Bianchi\n A, \n \n Martini\n M, \n \n Molinari\n F, \n \n Veronese\n S, \n \n Nichelatti\n M, \n \n Artale\n S\n \n et al\n . PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res2009;69(5):1851\u20131857"},{"issue":"1","key":"i0020-8868-99-6-795-b17","series-title":"Ann Oncol","first-page":"84","article-title":"PI3KCA\/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients","volume":"20","author":"Perrone\n F,","year":"2009","unstructured":"Perrone\n F, \n \n Lampis\n A, \n \n Orsenigo\n M, \n \n Di Bartolomeo\n M, \n \n Gevorgyan\n A, \n \n Losa\n M\n \n et al\n . PI3KCA\/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol2009;20(1):84\u201390"}],"container-title":["International Surgery"],"original-title":[],"link":[{"URL":"https:\/\/international-surgery.kglmeridian.com\/view\/journals\/insu\/99\/6\/article-p795.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/international-surgery\/article-pdf\/99\/6\/795\/2348535\/intsurg-d-13-00125_1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/international-surgery.kglmeridian.com\/downloadpdf\/journals\/insu\/99\/6\/article-p795.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/international-surgery.kglmeridian.com\/downloadpdf\/journals\/insu\/99\/6\/article-p795.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:10:02Z","timestamp":1751483402000},"score":1,"resource":{"primary":{"URL":"https:\/\/international-surgery.kglmeridian.com\/view\/journals\/insu\/99\/6\/article-p795.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":17,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.9738\/intsurg-d-13-00125.1","relation":{},"ISSN":["0020-8868","2520-2456"],"issn-type":[{"type":"print","value":"0020-8868"},{"type":"electronic","value":"2520-2456"}],"subject":[],"published":{"date-parts":[[2014]]}}}